Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients - Wikidata - wikimedia - TriplyDB

Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients

Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients

http://www.wikidata.org/entity/Q35008290

about

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.

P2860

Q39190318-E4450FF6-3DF8-4FBF-87DE-5529A55FC5E8

P2860

Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients

http://www.wikidata.org/entity/Q35008290

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Cost-effectiveness analysis of ...... f early breast cancer patients

@ast

Cost-effectiveness analysis of ...... f early breast cancer patients

@en

type

label

Cost-effectiveness analysis of ...... f early breast cancer patients

@ast

Cost-effectiveness analysis of ...... f early breast cancer patients

@en

prefLabel

Cost-effectiveness analysis of ...... f early breast cancer patients

@ast

Cost-effectiveness analysis of ...... f early breast cancer patients

@en

P1433

Q35008290-DC250E0B-8339-407E-8AE5-1BFD7A848DDE

P1476

Q35008290-F067844B-C238-4ED5-98CF-A80B9D8F1B08

P2093

Q35008290-0AEF38A5-7CAF-4CA5-90AD-4F13F0AC7EF8

Q35008290-1C6F46B3-6B9C-402E-A4DC-2DF87A8834C8

Q35008290-251AA547-9A68-4666-BD6D-84B2ACC97153

Q35008290-3E44F155-6126-4586-BF21-21C505FF52ED

Q35008290-3FB66EEE-B183-4735-AF48-475D6FEA39B3

Q35008290-A81D6481-FEF2-4A8C-BA58-3C948630C800

Q35008290-BE167854-88A5-4091-B503-66D3A848EAFD

Q35008290-C2BE60BC-88D8-411B-915E-54C85F68EE0A

Q35008290-C2FD6161-B4A2-43A3-BBAB-A33DA1F81948

Q35008290-F25D25AE-6591-45F1-A58B-8C0C11D83368

P2860

Q35008290-050B10C1-FB05-478F-8EBA-11993E7DBC21

Q35008290-0527E181-871B-48DB-88FF-0273399EAAA3

Q35008290-0644F9F9-8FDB-4C8A-B59C-0453ACF29D3B

Q35008290-08EE8915-55EA-4214-A8B9-D7169DCD77F4

Q35008290-0D38F06A-00D4-45FA-9851-F2E8DA9610D5

Q35008290-0FC905C3-9A2A-4C03-B7D4-B746327F840E

Q35008290-10540894-494F-4B6A-8B3E-B7D713FACC7E

Q35008290-11828D1F-CA43-4CDB-BAEE-DF24DED2B39A

Q35008290-17179398-07FC-470E-ACA4-AACC77821754

Q35008290-193061F0-8B51-45C7-B7AB-4A680627842E

P2888

Q35008290-6DEC74A3-E3E4-4357-9B2E-2B05BEDEB4C0

P304

Q35008290-2DE01C39-9596-427E-84A9-F0EB582DC5B7

P31

Q35008290-759D329E-2441-4DAD-AC68-8C52418B423C

P356

Q35008290-5B060730-53A3-40C3-84C2-E8B05D5582D3

P433

Q35008290-83EBA54D-20AB-4365-9068-F1567C157859

P478

Q35008290-C7BBA187-9351-4808-ABB4-59D8B9BE9CB3

P50

Q35008290-25EC3DF0-3BDE-4FD3-A887-ED4736FA1E0A

Q35008290-2DB211A7-FD03-4B11-AE8E-14D6F4290785

Q35008290-50574A19-0CB4-4B40-8032-C8C99DE019E8

Q35008290-D04F3488-4423-4213-8230-91B9F09E87AD

P577

Q35008290-B689FB1A-7202-4E52-8A41-8CBB8D4E2E21

P5875

Q35008290-92425841-B843-4440-BDA2-59A8085AEFED

P698

Q35008290-74912857-D40A-4ABD-9F95-9522063D7941

P932

Q35008290-C66D425E-94E5-4C2D-AB02-FBD3486484A1

P356

S40273-014-0227-X

P1433

PharmacoEconomics

P1476

Cost-effectiveness analysis of ...... f early breast cancer patients

@en

P2093

Florian Gutzwiller

http://www.w3.org/2001/XMLSchema#string

Jan C Brase

http://www.w3.org/2001/XMLSchema#string

Karsten E Weber

http://www.w3.org/2001/XMLSchema#string

Margaretha Rudas

http://www.w3.org/2001/XMLSchema#string

Martin Filipits

http://www.w3.org/2001/XMLSchema#string

Peter Dubsky

http://www.w3.org/2001/XMLSchema#string

Ralf Kronenwett

http://www.w3.org/2001/XMLSchema#string

Richard Greil

http://www.w3.org/2001/XMLSchema#string

Sibylle Loibl

http://www.w3.org/2001/XMLSchema#string

Thomas D Szucs

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

EuroQol: the current state of play.

One thousand health-related quality-of-life estimates.

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

First Revision of the German S3 Guideline 'Diagnosis, Therapy, and Follow-Up of Breast Cancer'

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

P2888

s40273-014-0227-x

P304

179-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-014-0227-X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Schwenkglenks

Patricia R Blank

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269412586

http://www.w3.org/2001/XMLSchema#string

P698

25404424

http://www.w3.org/2001/XMLSchema#string

P932

4305105

http://www.w3.org/2001/XMLSchema#string